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ABSTRACT: The SAR of 4-hydroxybenzaldehyde inhibitors of the trypanosomal alternative oxidase (TAO), a critical enzyme for 
the respiration of bloodstream forms trypanosomes, was investigated. Replacing the aldehyde group with a methyl ester resulted in a 
10-fold increase in TAO inhibition and activity against T. brucei. Remarkably, two analogues containing the 2-hydroxy-6-methyl 
scaffold (9e and 16e) displayed single digit nanomolar TAO inhibition, which represents the most potent 4-alkoxybenzoic acid de-
rivatives described to date. 9e was 50-times more potent against TAO and 10-times more active against T. brucei compared to its 
benzaldehyde analogue 23. The farnesyl derivative 16e was as potent a TAO inhibitor as ascofuranone with IC50 = 3.1 nM. Similar 
to ascofuranone derivatives, the 2-hydroxy and 6-methyl groups seemed essential for low nanomolar TAO inhibition of acid deriva-
tives, suggesting analogous binding interactions with the TAO active site.  
The bloodstream forms (BSF) of African trypanosomes, 
which cause sleeping sickness in humans and animal trypano-
somiasis (nagana) in livestock, rely exclusively on glucose me-
tabolism for energy production. Lacking a functional oxidative 
phosphorylation pathway, BSF trypanosomes use the trypano-
some alternative oxidase (TAO) as terminal oxidase to re-oxi-
dize the NADPH that accumulates during glycolysis. TAO is a 
non-haem cyanide–insensitive membrane-bound di-iron pro-
tein that catalyzes the oxidation of ubiquinol and the four elec-
tron reduction of oxygen to water.1 This enzyme, which is es-
sential for the respiration of BSF trypanosomes2 and is con-
served among T. brucei subspecies,3 has been validated as a 
drug target against trypanosomes.4-7 
In recent years, different series of TAO inhibitors have been 
reported that are based on the structure of the natural isoprenoid 
antibiotic ascofuranone (Figure 1).8-12 Kita’s group reported the 
pharmacophore of ascofuranone8 and, shortly after, the 3-D 
structures of TAO in the presence and absence of ascofuranone 
derivatives, allowing a better understanding of inhibitor binding 
modes.13 However, to date ascofuranone is the only TAO inhib-
itor among the ascofuranone-based compounds that has shown 
in vivo curative activity in different mouse models of trypano-
somiasis.6, 14 The modest success of the ascofuranone-like in-
hibitors against T. brucei is attributed due to poor physicochem-
ical (drug-like) properties of these compounds, as they are 
highly lipophilic and hardly soluble in water, resulting in poor 
pharmacokinetic properties. In these inhibitors, a high degree of 
lipophilicity is required not only for effective binding to TAO8 
(i.e. a hydrophobic tail is necessary, Figure 1) but probably also 
to retain the inhibitors in the mitochondrial membrane where 
TAO is located.11 The requirement for these properties has ham-
pered the search for inhibitors with drug-like properties.  
Recently, we have developed different series of TAO inhibi-
tors based on the 4-hydroxybenzoate and 4-alkoxybenzalde-
hyde chemotypes (Figure 1, A and D). These compounds dis-
played submicromolar to low nanomolar IC50 values against re-
combinant TAO (rTAO) and micromolar activities against T. 
brucei. The conjugation of these inhibitors with a mitochon-
drion-targeting lipophilic cation tail via a methylene linker 
yielded very potent trypanocides against wild-type and multi-
drug-resistant T. brucei strains.15, 16 In particular, compound A 
(R1 = 
+PPh3, IC50 (rTAO) = 0.09 µM) was able to reduce the para-
site load of mice infected with T. b. brucei rhodesiense by ip 
administration at 4×10 mg/kg.15  
In spite of the promising initial in vivo results, the benzoate 
derivatives A present several drawbacks: 1) a metabolic liability 
dependent on the substituents of the aromatic head (i.e. limiting 
the options for SAR development); 2) less than optimum water 
solubility; 3) a reduced therapeutic window in vivo (e.g. dosage 
> 4×10 mg/kg/ip was not tolerated, unpublished data). In con-
trast, the 4-alkoxy inhibitors (e.g. B–D), which are devoid of an 
ester bond, are expected to be resistant to serum hydrolases. In 
fact, compound 1 (Figure 1, D) proved to be stable in mouse 
 serum although it appeared to bind serum proteins to high de-
gree.15 This behavior was attributed to the presence of the ben-
zaldehyde group which may form Schiff’s bases with the amino 
groups of the proteins. 
 
Figure 1. Structure of different TAO inhibitors chemotypes: 
ascofuranone, 4-hydroxybenzoates (A),15, 16 4-alkoxybenzoic 
acids (B),17 and 4-alkoxybenzaldehydes (C, D).12, 15 The main 
interactions of ascofuranone-like inhibitors with the TAO ac-
tive site are shown in green color.8, 13 The predicted main inter-
actions of 4-alkoxybenzaldehyde D with the amino acids of the 
TAO active site15 are highlighted in red color. HB = hydrogen 
bond.  
In the current work, we further investigated the SAR of this 
promising TAO inhibitor scaffold by replacing the aldehyde 
group of D with a carboxylic acid (or ester), modulating the na-
ture of the lipophilic tail (e.g. alkyl, geranyl, farnesyl) and of 
the substituent on the aromatic ring (Figure 2). In the designed 
compounds, the carboxylic acid function is expected to be in 
close proximity to the diiron center of TAO whereas the oxygen 
atom in 4-position is expected to engage in hydrogen bond (HB) 
interactions with polar amino acids from the TAO binding site 
(e.g. Arg118) similarly to 1 (Figure 1). The presence of a free 
acid group in the molecule should enhance the water solubility 
of the molecules.  
 
Figure 2. Structural modifications of 4-alkoxybenzoic acid de-
rivatives studied in this work. 
Results and discussion. The inhibitors with a lipocation alkyl 
tail (6a, 7a-e, 10b, 10c, and 10e) were synthesized in two steps 
starting from the corresponding 4-hydroxybenzoates 2a-e 
(Scheme 1). Alkylation of 2a with 1,10-dibromodecane and Na-
HCO3 gave the bromoalkoxy compound 4a with low yield 
(22%). Better yields of 5a-e (43–67%) were obtained using the 
Mitsunobu protocol18 with 14-bromotetradecan-1-ol.19 Nucleo-
philic substitution of these bromo derivatives with tri-
phenylphosphine or quinoline yielded the phosphonium (6a, 
7a-e) and quinolinium salts (10b, 10c, 10e). Smooth hydrolysis 
of the ester function with potassium carbonate20 in MeOH/H2O 
at 50 ºC yielded the carboxylic acids 8a and 9a-e with excellent 
yields. For the quinolinium salts, the hydrolysis was performed 
with 48% aqueous HBr to yield the acid derivatives 11b-e 
(Scheme 1). The TAO inhibitors with a farnesyl (15e) or gera-
nyl (17a-c, 17e) tail were synthesized from 2a-e by the 
Mitsunobu reaction using alcohols 12 and 13 (Scheme 2). Treat-
ment of 15e, 17a-c and 17e with KOH/MeOH at 60 ºC led to 
complete hydrolysis of the acetate and benzoate groups to give 
high yields of the carboxylic acids 16e, 18a-c, and 18e. Selec-
tive hydrolysis of the acetate group of 17a-e was performed 
with potassium carbonate to yield 19a-e, respectively. 
 
Scheme 1. Synthesis of TAO inhibitors with lipocation alkyl taila 
 
aReagents and conditions. (i) NaHCO3, CH3CN, 65 ºC; (ii) DIAD, Ph3P, THF, 0 ºC to rt; (iii) Ph3P, CH3CN, 80 ºC; (iv) K2CO3 (3 
eq.), MeOH/H2O (5/1) or EtOH/H2O (5/1, for 7e), 50 ºC; (v) Quinoline, CH3CN, 80 ºC; (vi) HBr 48%, H2O, 60 ºC. 
 Scheme 2. Synthesis of TAO inhibitors with geranyl and far-
nesyl taila  
 
aReagents and conditions. (i) 1) SeO2, 
tBuOOH, salicylic acid 
(cat.), CH2Cl2, 30 min, rt; 2) geranyl acetate or farnesyl acetate, 
45 h, rt; (ii) CBr4, Ph3P, CH2Cl2; (iii) DIAD, Ph3P, THF, 0 ºC to 
rt; (iv) 1) 1M KOH, MeOH, 60 ºC, 2) 1M HCl; (v) K2CO3, 
MeOH, rt (for 17a) or K2CO3, EtOH, 35 ºC (for 17e). 
The compounds were assayed as inhibitors of the ubiquinol ox-
idase activity of purified ΔMTS-TAO as described.15 
Cationic TAO inhibitors: The replacement of the aldehyde 
group of 23 by a methyl ester (7a) led to a 15-fold increase in 
TAO inhibition potency resulting in a 7-fold improvement in 
activity against T. brucei (Table 1).In this methyl ester series, 
replacement of the 2-OH group by a fluorine (7b) or methyl 
substituent (7c) resulted in 50- and >300-fold decreased inhibi-
tion compared with 7a, respectively (2-OH > 2-F>> 2-
CH3).These data confirmed the need of a hydrogen bond-form-
ing substituent at this position for tight binding to TAO. As 
noted earlier with the 4-hydroxybenzoate series,15, 16 a meth-
ylene linker of less than C14 was detrimental to TAO inhibition 
(compare 6a/7a). Switching the 4-alkoxy tail (7a) to the 3-po-
sition (7d) of the aromatic ring hardly influenced TAO inhibi-
tion (0.015 and 0.012 µM, respectively), which correlated with 
similar trypanocidal activities for both compounds (0.018 and 
0.028 µM, respectively).  
Interestingly, TAO inhibition was limited by the size of the es-
ter substituent at C1: an ethyl ester substituent was detrimental 
with a 60-fold drop in inhibitor potency compared to the free 
acid (compare 7e/9e, 15e/16e). The same trend was observed 
for the geranyl series (Table 2) with higher IC50 values for the 
ethyl ester 19e (>5 µM) compared to the free acid 18e (2.4 µM). 
Intriguingly, replacement of the methyl ester (7a and 7b) or al-
dehyde group (23) at C1 by a carboxylic acid led to a drastic 
loss of inhibition (IC50 >5 µM for 9a and 9b). In contrast, the 2-
hydroxy-6-methyl acid analogue 9e inhibited TAO in the low 
nanomolar range (IC50 = 4.2 nM) indicating that the presence of 
the 6-methyl substituent in 9e is playing a key role in the bind-
ing of inhibitors with an acid functional group, similar to the 
ascofuranone-based inhibitors.8 The triphenylphosphonium cat-
ion was more favorable than the 1-quinolinium cation for upper 
inhibition of TAO (compare 7e/10e, 7b/10b). In this series of 
quinolinium salts, an aldehyde group at C1 (24, IC50 = 1.23 µM) 
was superior to an ester or acid group (IC50 > 5 µM). 
Non-cationic inhibitors with methylene, geranyl, and farnesyl 
tail: the acid derivative 15e with a farnesyl lipophilic tail was 
the most potent inhibitor of these series (IC50 = 3.1 nM), supe-
rior to the geranyl counterpart 18e and the rest of geranyl acid 
derivatives (18a–c) which were single digit micromolar inhibi-
tors (Table 2). Remarkably, one extra isoprenyl unit (15e) was 
responsible for an increase of inhibition by 3 orders of magni-
tude within this series. In contrast, the benzoate derivatives 
(15e, 17a, 17c, 19b, 19e) were much less potent TAO inhibitors 
(IC50 > 5 µM), with the exception of 5a and 19c (IC50 ≈ 2 µM). 
These inhibition values are in the same range as previously re-
ported TAO inhibitors bearing a 4-alkoxy isoprenoid chain such 
as B (ACB41, Ki = 5µM)
17 or C (IC50 = 1 µM).
12, 17 We decided 
to study whether a geranyl tail would have the same (weak) ef-
fect on the inhibitory potency of the benzoate series derived 
from scaffold A. The benzoate derivative 20a with the geranyl 
tail at C1 was synthesized by reaction of 1 equivalent of 2,4-
dihydroxybenzoic acid and 1 equivalent of 14 in the presence 
of potassium carbonate in anhydrous acetone at 60 ºC. The 
product of dialkylation 21a was also isolated by silica chroma-
tography (Scheme 3).  
Scheme 3. Synthesis of 4-hydroxybenzoate inhibitor 20a. 
 
aReagents and conditions. (i) K2CO3, acetone, 60 ºC, 2 h. 
Compound 20a inhibited TAO in the low nanomolar range (IC50 
= 9.1 nM), with a potency similar to that of its 14-bromotetra-
decane benzoate analogue (10.8 nM).15 This results indicates 
that the geranyl tail is a valid biososteric replacement of the 
methylene tail for the 4-hydroxybenzoate inhibitor series (A) 
but it is less effective for the 4-alkoxybenzoic acid derivatives. 
Not surprisingly, the disubstituted derivative 21a with the 4-OH 
position blocked by the 4-alkoxygeranyl group inhibited TAO 
poorly (> 5 µM). The 4-hydroxybenzoate inhibitors are ex-
pected to bind TAO with the 4-OH group close to the diiron 
catalytic center, which is not possible with this disubstituted 
compound.  
The trypanocidal activity of the new compounds was assessed 
against wild-type and multidrug-resistant strains of T. b. brucei. 
 In the cationic series, the triphenylphosphonium conjugates 
(7b, 7c, 7e) were 6- to 48-times more potent than the quinolin-
ium salts (10b, 10c, 10e; Table 1) in agreement with previous 
results.15, 16 However, the benzoates quinolinium salts 10c and 
10e were 5- to 10-fold more potent than the benzaldehyde hit 1 
(EC50 = 1.75 µM). Replacing the aldehyde group (1, R3 = H) by 
a methyl ester function (7a, R3 = OMe) resulted in a 7-fold in-
crease in trypanocidal activity against T. b. brucei. In this ben-
zoate series, replacement of the 2-OH with a 2-Me (7c) had no 
influence on the activity whereas a 2-F (7b) or (2-OH, 6-Me) 
substituents (7e) gave slightly less potent compounds (2.5-
fold). The influence on trypanocidal activity of a free acid group 
in R3 depended on the nature of the substituents R1 and R2; the 
benzoate derivatives 7b (R2 = F, R3 = H) and 7e (R2 = Me, R3 = 
OH) were 1.4- to 4-times less active than the free acids 9b and 
9e, respectively. In contrast, the benzoates 7a (R1 = OH, R2 = 
H), 7c and 10c (R1= Me, R2 = H) were 5-, 10-, and 66-times 
more active than the free acids 9a, 9c and 11c, respectively.  
Table 1. Biological evaluation of 4-alkoxybenzoate-lipoca-
tion conjugates against rTAO (IC50, µM), T. b. brucei (EC50, 
µM), and human cells (CC50, µM). 
  
 
aPurified recombinant trypanosome alternative oxidase from T. 
b. brucei (n = 3). bTrypomastigotes of T. b. brucei s427. cCyto-
toxicity on human endothelial kidney cells. dSelectivity index = 
CC50/EC50 (T. brucei WT). 
eTaken from reference 15. fNot deter-
mined.  gAscofuranone. hSalicylhydroxamic acid. iPentamidine. 
jPhenylarsine oxide.  
The non-cationic benzoate inhibitors with a geranyl or farnesyl 
tail holding an OAc group (15e, 17a, 17c) displayed low mi-
cromolar activity against T. brucei (< 20 µM). In contrast, the 
inhibitors with a free acid group (18a–c, 18e, 16e) were all in-
active at the highest dose tested (100 µM), possibly due to poor 
uptake of these negatively charged carboxylate compounds 
(pKa < 5) into the trypanosomes’ mitochondria. The benzoate 
derivatives with a 14-bromotetradecane chain (5a–c) were in-
active except 5d (8.1 µM) and 5e (8.9 µM) which displayed IC50 
< 10 µM.  
Table 2. Biological evaluation of 4-alkoxybenzoates with al-
kyl, geranyl and farnesyl tail against rTAO (IC50, µM), T. b. 
brucei (EC50, µM), and human cells (CC50, µM). 
 
  
Footnotes and control drugs: see Table 1.  
Little difference in activity was observed between WT and the 
multidrug resistant cell line B48 with resistance factors (RF) 
close to 1 (Tables S1) ), indicating they do not utilise the known 
drug transporters TbAT1 and HAPT.21, 22 In contrast, several in-
hibitors (5d, 5e, 8a, 9c, 9e, 10b, 20a) were more effective 
against the T. brucei cell line from which all three aquaporins 
were deleted (AQP1-3 triple KO23). These trypanosomes are 
particularly sensitive to TAO inhibitors because they cannot 
dispose of the glycerol produced in large quantity under anaer-
obic conditions (i.e. when TAO is inhibited). Accumulation of 
glycerol is toxic to the cells as a result of the inhibition of the 
glycerol kinase and depletion of ATP production.14, 24 The same 
compounds were also significantly more effective against T. b. 
brucei WT (RF < 1) when co-incubated with 5 mM glycerol, 
which inhibits the anaerobic ATP production pathway (Tables 
S1). Analogous results were obtained with the benzaldehyde in-
hibitors 1, 22, and 23,15 supporting the view that TAO is highly 
likely to be the main target of 5d, 5e, 8a, 9c, 9e, 10b, and 20a. 
In contrast, compounds 7b, 7c, 7e, 9a, and 9b appeared to be 
less dependent on TAO inhibition as shown by the RF > 2 
against the AQP1-3 knockout line and against T. b. brucei 
WT+glycerol indicating that these compounds probably have 
Cmpd n R1 R2 R3 rTAOa T. b. brucei WTb HEK cells
c 
 
SId 
 
1e 14 OH H H 0.22 ± 0.01 0.133 ± 0.003 >200 >1500 
6a 10 OH H OMe >5 0.002 ± 0.001 0.44 ± 0.02 184 
7a 14 OH H OMe 0.015 ± 0.003 0.018 ± 0.003 NDf  
7b 14 F H OMe 0.74 ± 0.04 0.05 ± 0.01 0.22 ± 0.04 4.5 
7c 14 Me H OMe >5 0.018 ± 0.004 0.35 ± 0.01 19 
7e 14 OH Me OEt 0.250 ± 0.011 0.05 ± 0.01 0.63 ± 0.01 13 
7d 14 OH H OMe 0.012 ± 0.008 0.028 ± 0.02 0.64 ± 0.03 10 
8a 10 OH H OH >5 0.73 ± 0.01 8.2 ± 0.1 11 
9a 14 OH H OH >5 0.086 ± 0.005 19.6 ± 1.3 227 
9b 14 F H OH >5 0.037 ± 0.001 8.35 ± 0.53 225 
9c 14 Me H OH >5 0.19 ± 0.01 4.24 ± 0.10 22 
9e 14 OH Me OH 0.0042 ± 0.0002 0.013 ± 0.003 0.83 ± 0.06 64 
10b 14 F H OMe >5 2.4 ± 0.1 3.36 ± 0.18 1.4 
10c 14 Me H OMe >5 0.16 ± 0.01 0.30 ± 0.04 1.9 
10e 14 OH Me OEt >5 0.29 ± 0.05 0.61 ± 0.001 2.1 
11c 14 Me H OH >5 10.6 ± 0.5 24.4 ± 2.8 2.3 
23h 14 OH H H 1.23 1.75 ± 0.01 >200 >114 
AFg     0.002 ± 0.0004    
SHAMh     5.93 ± 0.13 62.9 ± 0.6   
Penti      0.0042 ± 0.0009   
PAOj       1.1 ± 0.15  
 
Cmpd R1 R2 rTAO
a T. b. brucei WTb HEK cells
c 
 
SId 
 
22c H H 0.073 ± 0.011 17.6 ± 0.5   
5a H OMe 2.3 ± 0.2 NE/100 ND  
5e Me OEt >5 8.9 ± 1.2 29.6 ± 5.6 3.3 
5d   >5 8.1 ± 1.0 28.6 ± 0.4 3.5 
15e OAc OEt >5 6.6 ± 1.3 20.8 ± 4.8 3.1 
16e OH OH 0.0031±0.0004 NE/100 ND  
17a OH OMe >5 19.3 ± 1.3 31.8 ± 4.2 1.7 
17c Me OMe >5 17.0 ± 0.5 45.1 ± 1.2 2.7 
18a OH OH 2.1 ± 0.4 NE/100 ND  
18b F OH 1.1 ± 0.1 NE/100 ND  
18c Me OH 0.92 ± 0.15 NE/100 ND  
19a OH OMe ND ND ND  
19b F OMe >5 NE/100 >100  
19c Me OMe 1.69 ± 0.38 NE/100 >100  
19e  OEt >5 ND ND  
18e  OH 2.4 ± 0.5 NE/100 ND  
 
 multi-target activity. Cytotoxicity against HEK cells was low (> 
20 µM) for the non-cationic inhibitors with a geranyl (17a, 17c, 
20a), farnesyl (15e) and methylene (5d, 5e) tail, and the cationic 
inhibitors with a free acid group (8a, 9a–c) (CC50 > 4 µM, SI 
from 11 to 227). In contrast, the inhibitor 9e was more cytotoxic 
(CC50 = 0.83 µM) although this still yielded selectivity indexes 
of 64 and 230 towards T. brucei WT and AQP1-3 knockout 
strains, respectively. Other inhibitors with a lipocation tail dis-
played variable cytotoxicity against human cells (CC50 < 1 µM 
for 6a, 7a–d; CC50 > 20 µM for 11c). 
In summary, cationic 4-alkoxy benzoic acid derivatives are 
more potent TAO inhibitors than their benzaldehyde counter-
parts. The 2,4-dihydroxy-6-methyl carboxylic acid scaffold, in 
particular, gave the most potent TAO inhibitors (9e, 16e). Most 
of the 4-alkoxybenzoate-lipocation conjugates were also effec-
tive nanomolar range trypanocides. However, higher toxicity 
against human cells was observed resulting in lower selectivity 
indexes compared with previous series. 
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